Evidence map›Paper›PMID 34456921›Full record

ArticleFrontiers in immunology2021

Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity.

Eric Alves, Emily McLeish, Pilar Blancafort, Jerome D Coudert, Silvana Gaudieri

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. [Research progress of the ULBP-NKG2D axis in autoimmune diseases].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Eric AlvesSchool of Human Sciences, The University of Western Australia, Perth, WA, Australia.
Emily McLeishCentre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, WA, Australia.
Pilar BlancafortSchool of Human Sciences, The University of Western Australia, Perth, WA, Australia.
Jerome D CoudertCentre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, WA, Australia.
Silvana GaudieriSchool of Human Sciences, The University of Western Australia, Perth, WA, Australia.
Murdoch University · AUHarry Perkins Institute of Medical Research · AUThe University of Notre Dame Australia · AUThe University of Texas Health Science Center at San Antonio · US

Funding

Targeted epigenetic silencing of oncogenic Transcription Factors (PQ18)R01CA170370 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLANCAFORT, PILAR · 2012 to 2015
$900k
Precision engineering of DNA methylation patterns in the human genomeR01DA036906 · NIDA · UNIVERSITY OF WESTERN AUSTRALIA · PI BLANCAFORT, PILAR, LISTER, RYAN · 2013 to 2014
$350k
NCI NIH HHS R01 CA170370NIDA NIH HHS R01 DA036906
6 · The paper itself

Abstract

The activating immune receptor natural killer group member D (NKG2D) and its cognate ligands represent a fundamental surveillance system of cellular distress, damage or transformation. Signaling through the NKG2D receptor-ligand axis is critical for early detection of viral infection or oncogenic transformation and the presence of functional NKG2D ligands (NKG2D-L) is associated with tumor rejection and viral clearance. Many viruses and tumors have developed mechanisms to evade NKG2D recognition

Indexed as

CRISPR-Cas SystemsGene EditingDisease ResistanceDisease SusceptibilityEpigenesis, GeneticGenetic TherapyHost-Pathogen InteractionsHumansImmunityLigandsNeoplasmsNK Cell Lectin-Like Receptor Subfamily KProtein BindingVirus DiseasesKLRK1 protein, humanLigandsNK Cell Lectin-Like Receptor Subfamily KcancerCRISPRimmune evasionimmunotherapyNK cellsNKG2Dprecision medicineviral infection

Identifiers

PMID34456921
PMCPMC8397441
OpenAlexW3194369226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.